NEW YORK, NY / ACCESSWIRE / December 26, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BAX Shareholders Click Here: https://www.zlk.com/pslra-1/baxter-international-inc-loss-form?prid=5050&wire=1
REZI Shareholders Click Here: https://www.zlk.com/pslra-1/resideo-technologies-inc-loss-form?prid=5050&wire=1
PRU Shareholders Click Here: https://www.zlk.com/pslra-1/prudential-financial-inc-loss-form?prid=5050&wire=1

* ADDITIONAL INFORMATION BELOW *

Baxter International Inc. (NYSE:BAX)

BAX Lawsuit on behalf of: investors who purchased February 21, 2019 – October 23, 2019
Lead Plaintiff Deadline : January 24, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/baxter-international-inc-loss-form?prid=5050&wire=1

According to the filed complaint, during the class period, Baxter International Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) the Company lacked effective internal control over financial reporting; (3) as a result, the Company's financial statements were misstated and would likely require correction or amendment; (4) due to the Company's internal investigation, Baxter would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on Form 10-Q in a timely manner; and (5) as a result of the foregoing, Defendants' statements about the Company's business and operations lacked a reasonable basis.

Resideo Technologies, Inc. (NYSE:REZI)

REZI Lawsuit on behalf of: investors who purchased October 29, 2018 – October 22, 2019
Lead Plaintiff Deadline : January 7, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/resideo-technologies-inc-loss-form?prid=5050&wire=1

According to the filed complaint, during the class period, Resideo Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the negative operational effects of the Company's spin-off from Honeywell International Inc. were more substantial and persistent than disclosed and had negatively affected Resideo's product sales, supply chain, and gross margins, putting the Company's FY19 financial forecasts at risk; and (b) as a result of the foregoing, the Company's financial guidance lacked a reasonable basis and the Company was not on track to make its FY19 guidance as claimed.

Prudential Financial, Inc. (NYSE:PRU)

PRU Lawsuit on behalf of: investors who purchased February 15, 2019 – August 2, 2019
Lead Plaintiff Deadline : January 27, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/prudential-financial-inc-loss-form?prid=5050&wire=1

According to the filed complaint, during the class period, Prudential Financial, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the Company's reserve assumptions failed to account for adversely developing mortality experience in the Individual Life business segment; (b) the Company was not over-reserved, but instead, its reported reserves, particularly for the Individual Life business segment, were insufficient to satisfy its future policy benefits liabilities; and (c) the Company had materially understated its liabilities and overstated net income as a result of flawed assumptions in calculating mortality experience.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 571353

NEW YORK, NY / ACCESSWIRE / December 26, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Wanda Sports Group Company Limited (NASDAQ:WSG)

Investors Affected : Wanda Sports' securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Wanda Sports' July 26, 2019 initial public offering.

A class action has commenced on behalf of certain shareholders in Wanda Sports Group Company Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the lack of major sporting events for its Digital, Production, Sports Solutions ("DPSS") and Spectator Sports segments for its second quarter of 2019, ending before the initial public offering, would negatively impact revenue for the second quarter of 2019; (2) Wanda Sports had suffered a year-over-year decrease in revenue in its second quarter ended June 30, 2019 and would for its fiscal year 2019, primarily related to lower reimbursement revenues accounted for in its DPSS segment and lack of Spectator Sport segment offsets; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/wanda-sports-group-company-limited-loss-submission-form/?id=5049&from=1

UP Fintech Holding Limited (NASDAQ:TIGR)

Investors Affected : all persons and entities that purchased or otherwise acquired: (a) Fintech American Depository Shares pursuant and/or traceable to the Company's initial public offering conducted on or about March 20, 2019; or (b) Fintech securities between March 20, 2019 and May 16, 2019.

A class action has commenced on behalf of certain shareholders in UP Fintech Holding Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Fintech was experiencing a material decrease in commissions because of a negative trend related to risk-averse investors in the market; (ii) Fintech was unable to absorb costs associated with the rapid growth of its business and its status as a publicly listed company on a U.S. exchange; (iii) Fintech was incurring significant additional expenses related to, inter alia, employee headcount and employee compensation and benefits; (iv) all of the foregoing had led to Fintech significantly increasing operating costs and expenses; and (v) as a result, the documents filed by the Company in connection with the initial public offering were materially false and/or misleading and failed to state information required to be stated therein, and the Company's Class Period statements were likewise materially false and/or misleading.

Shareholders may find more information at https://securitiesclasslaw.com/securities/up-fintech-holding-limited-loss-submission-form/?id=5049&from=1

Merit Medical Systems, Inc. (NASDAQ:MMSI)

Investors Affected : February 26, 2019 – October 30, 2019

A class action has commenced on behalf of certain shareholders in Merit Medical Systems, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the integrations of acquired companies Cianna Medical, Inc. and Vascular Insights, LLC, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during FY19; and (c) in light of the foregoing, the Company's reported financial guidance for FY19 and FY20 was made without a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/merit-medical-systems-inc-loss-submission-form/?id=5049&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 571352

NEW YORK, NY / ACCESSWIRE / December 26, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Sealed Air Corporation (NYSE:SEE)
Class Period: November 5, 2014 to August 6, 2018
Lead Plaintiff Deadline: December 31, 2019

The SEE lawsuit alleges that throughout the class period, Sealed Air Corporation made materially false and/or misleading statements and/or failed to disclose that: (a) Sealed Air had hired its auditor, E&Y, pursuant to a conflicted and improper process and in order to help facilitate defendants' efforts to engage in accounting fraud; (b) Sealed Air's deduction of $1.49 billion in connection with the Settlement was indefensible and done for the improper purpose of artificially inflating the Company's financial results; (c) Sealed Air had artificially inflated its earnings, cash flows, and operating income during the Class Period; (d) as a result of the above, Sealed Air's Class Period financial statements were materially false and misleading and not prepared in conformance with GAAP; and (e) as a result of the above, Sealed Air's statements regarding its financial results, business, and prospects were materially misleading.

Learn about your recoverable losses in SEE: http://www.kleinstocklaw.com/pslra-1/sealed-air-corporation-loss-submission-form?id=5048&from=1

The RealReal, Inc. (NASDAQ:REAL)
Class Period: all persons and entities who purchased RealReal common stock pursuant and/or traceable to the Company's registration statement issued in connection with the Company's June 27, 2019 initial public offering.
Lead Plaintiff Deadline: January 24, 2020

The REAL lawsuit alleges that The RealReal, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's employees received little training on how to spot fake items; (2) the Company's strict quotas on its employees exacerbated product authentication issues; (3) consequently, the potential for counterfeit or mislabeled items to make it through Company's authentication process was higher than disclosed; and (4) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in REAL: http://www.kleinstocklaw.com/pslra-1/the-realreal-inc-loss-submission-form?id=5048&from=1

Fiat Chrysler Automobiles N.V. (NYSE:FCAU)
Class Period: February 26, 2016 to November 20, 2019
Lead Plaintiff Deadline: January 31, 2020

The FCAU lawsuit alleges that throughout the class period, Fiat Chrysler Automobiles N.V. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company employed a bribery scheme to obtain favorable terms in its collective bargaining agreement with United Automobile, Aerospace and Agricultural Implement Workers of America; (2) high-ranking Fiat officials were aware of and authorized the scheme; and (3) as a result, Defendants' statements about Fiat's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in FCAU: http://www.kleinstocklaw.com/pslra-1/fiat-chrysler-automobiles-n-v-loss-submission-form?id=5048&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 571351

NEW YORK, NY / ACCESSWIRE / December 26, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Azz, Inc. (NYSE:AZZ)
Class Period: July 3, 2018 to October 8, 2019
Lead Plaintiff Deadline: January 3, 2020

The complaint alleges that throughout the class period Azz, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s internal controls over financial reporting were not effective; (2) the Company improperly implemented ASC 606 which resulted in improper revenue reconciliations; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in AZZ: http://www.kleinstocklaw.com/pslra-1/azz-inc-loss-submission-form?id=5047&from=1

Yunji Inc. (NASDAQ:YJ)
Class Period: on behalf of shareholders who purchased or otherwise acquired Yunji American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s May 2019 initial public offering.
Lead Plaintiff Deadline: January 13, 2020

The YJ lawsuit alleges that Yunji Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was shifting certain of its sales to its marketplace platform; (2) this supply chain restructuring was likely to disrupt Yunji’s relationships with suppliers; (3) this supply chain restructuring was likely to have an adverse impact on the Company’s financial results; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in YJ: http://www.kleinstocklaw.com/pslra-1/yunji-inc-loss-submission-form?id=5047&from=1

Armstrong Flooring, Inc. (NYSE:AFI)
Class Period: March 6, 2018 to November 4, 2019
Lead Plaintiff Deadline: January 14, 2020

The AFI lawsuit alleges that throughout the class period, Armstrong Flooring, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had engaged in channel stuffing to artificially boost sales; (2) the Company’s internal control over inventory levels was not effective; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis

Learn about your recoverable losses in AFI: http://www.kleinstocklaw.com/pslra-1/armstrong-flooring-inc-loss-submission-form?id=5047&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 571350

NEW YORK, NY / ACCESSWIRE / December 26, 2019 / announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Uniti Group Inc. (NASDAQGS:UNIT)
Class Period: April 20, 2015 to February 15, 2019
Lead Plaintiff Deadline: December 30, 2019

Throughout the class period, Uniti Group Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Uniti's financial results were not sustainable because its customer Windstream had defaulted on its unsecured notes; and (ii) as a result of the foregoing, Defendants' statements about Uniti's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in UNIT: http://www.kleinstocklaw.com/pslra-1/uniti-group-inc-loss-submission-form?id=5046&from=1

Mylan N.V. (NASDAQ:MYL)
Class Period: May 9, 2018 to May 6, 2019
Lead Plaintiff Deadline: February 14, 2020

The complaint alleges Mylan N.V. made materially false and/or misleading statements and/or failed to disclose that: (1) Mylan's Morgantown facility was in significant violation of the FDA's Current Good Manufacturing Practice regulations; (2) Mylan would need to engage in a massive restructuring and remediation program; (3) Mylan's North American Segment would be substantially impacted by said program, which would in turn materially impact Mylan's financial health; (3) Mylan lacked effective internal control over financial reporting; and (4) as a result of the foregoing, the Company's financial statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in MYL: http://www.kleinstocklaw.com/pslra-1/mylan-n-v-loss-submission-form?id=5046&from=1

Grubhub Inc. (NYSE:GRUB)
Class Period: July 30, 2019 to October 28, 2019
Lead Plaintiff Deadline: January 21, 2020

The complaint alleges that during the class period Grubhub Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) customer orders were actually declining, despite the massive investments that the Company had made to spur demand for and use of its platform; (ii) Grubhub's new customer additions were generating significantly lower revenues as compared to historic cohorts because these customers were more prone to using competitor platforms; (iii) Grubhub's vaunted business model under which it secured exclusive partnerships had failed, and Grubhub needed to engage in the same aggressive nonpartnered sales tactics embraced by its competitors to generate significant revenue growth; (iv) Grubhub was required to spend substantial additional capital in order to grow revenues and retain market share in the face of heightened competitive dynamics and market saturation, eviscerating the Company's profitability; and (v) Grubhub was tracking tens of millions of dollars below its revenue and earnings guidance and such guidance lacked any reasonable basis.

Learn about your recoverable losses in GRUB: http://www.kleinstocklaw.com/pslra-1/grubhub-inc-loss-submission-form?id=5046&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 571349

CPR Provides Fast, Affordable Repairs for Phones, Tablets, Laptops and Game Consoles

INDEPENDENCE, OH / ACCESSWIRE / December 26, 2019 / CPR Cell Phone Repair, the largest and fastest growing retail mobile device repair franchise network in North America, is pleased to announce the opening of a new store in Falls Church, VA. The CPR network congratulates store owner Yosef Zeru and his team.

To learn more about CPR Cell Phone Repair Falls Church, please visit: https://www.cellphonerepair.com/falls-church-va/.

"We are ecstatic to welcome Yosef Zeru and his team to the CPR network," said Chris Jourdan, Director of Franchise Operations. "We are confident that CPR Falls Church will provide their community with unprecedented service, and we wish them success in this journey."

Falls Church, VA, is located just miles from Washington, D.C. Colonists initially settled the city in the 1600s. The area is well known for The Fall Church vestrymen, George Washington and George Mason, during the American Revolution. A copy of the Declaration of Independence was even read from The Falls Church in the summer of 1776. Previously, Falls Church had been named the wealthiest county in the United States. Two Fortune 500 companies are headquartered in Falls Church. CPR Falls Church is conveniently located in an international shopping mall just 15 minutes from Washington, D.C.

"My team and I are excited to be a part of the CPR Cell Phone Repair network," said Yosef Zeru of his new venture. "With nine years of experience in the industry, I am proud to offer fast and affordable repairs. We are looking forward to serving residents of the D.C., Maryland, and Virginia metropolitan area."

Yosef grew up in Takoma Park, MD, and is a graduate of Capitol Technology University. When he's not working, Yosef enjoys visiting historical sights in the area. CPR Falls Church offers affordable repairs for mobile devices of all makes and models. Yosef and his team provide professional services to customers in need of cracked screen repair, water damage repair, and more. To learn more about CPR Falls Church, visit the store or contact them at the details below.

CPR Cell Phone Repair Falls Church is located at:
3825 S George Mason Dr
Suite J
Falls Church, VA 22041

Please contact the store at 703-209-0006 or via email: repairs@cpr-fallschurch.com
Please visit the website: https://www.cellphonerepair.com/falls-church-va/

About CPR Cell Phone Repair:

Founded in Orlando, Fla. in 1996, CPR Cell Phone Repair is the fastest growing wireless technology franchise in North America and operates over 800 locations internationally. As a pioneer and leader in the electronics repair industry, CPR offers same-day repair and refurbishing services for cell phones, laptops, gaming systems, digital music players, tablets, and other personal electronic devices. For four straight years, CPR was named in Entrepreneur Magazine's Franchise 500 list. In 2019, CPR was ranked in the top 25 of the list and placed as the number one business for tech businesses franchises. For more information about CPR Cell Phone Repair and franchise opportunities, visit https://www.cellphonerepair.com/ or call 877-856-5101.

Contact:

Mark Sweeterman
msweeterman@merrymtg.com
216-647-0645 x 617

SOURCE: CPR Cell Phone Repair

ReleaseID: 571344

NEW YORK, NY / ACCESSWIRE / December 26, 2019 / Healthcare Solutions Holdings, a medical service and device company focused on providing clinicians with state-of-the-art diagnostic and therapeutic tools, invites Dr. John Holtzman DPM, to discuss the benefits of utilizing topical creams and specialty pharmacy in lieu of prescription opioids.

Dr. John Holtzman

Over the years, the opioid epidemic ravaging so many American lives has become a top-tier concern of the doctors charged with protecting patients. Opioid abuse has thousands of deaths and billions of dollars spent each year on medical costs; in response, deep discussions of specialty pharmacy has begun amongst industry leaders. Dr. John Holtzman, a Board Certified Podiatrist based in St. Louis, Missouri, is spreading the word about his utilization of topical and specialty pharmacy in lieu of opioid prescriptions. "With the increasing amounts of deaths caused by opioids and the possibility of addiction to opioids, I use a lot of topical anti-inflammatories on the skin because it is effective and we can achieve direct pain relief without prescribing opioids," says Dr. Holtzman. "Compounding pharmacy gives physicians more flexibility to add, increase or decrease medications to a topical which you are not able to do with opioid pills. When applied to the skin, topical creams are a direct delivery of medications and very little is absorbed into the bloodstream so it is not going to throw off any medications the patient may be taken orally. With topical creams, I am also able to decrease oral medications and supply my patients with a topical cream containing the same medication [they were taking orally] or even a different drug that may work better."

Dr. Holtzman has found that using specialty compounding as an alternative to reduce prescriptions of opioids helpful for the patients' long-term care. "If a patient is solely on a prescribed opioid for pain, topical creams enable physicians to ween the patient off their opioid prescription. By doing this, long-term opioid prescriptions are reduced and the direct treatment of cream through the skin is better for the patient's long-term care. I have found topical creams to be very successful with my patients as the treatment is precise and effective for a specific area the patient is needing to address."

Dr. John Holtzman received his medical degree from Des Moines University's College of Podiatric Medicine and Surgery and went on to complete his surgical residency in reconstructive foot and ankle surgery through Deaconess Hospital in St. Louis, Missouri. Dr. Holtzman specializes in podiatric surgery and podiatry and has been in practice for more than 20 years, bringing his expertise to private practice

HSI is a medical service, and device company focused on providing clinicians with state-of-the-art diagnostic and therapeutic tools. Our mission is to improve patient outcomes by helping clinicians gain broader access to the most advanced technology in the healthcare industry. HSI focuses not only on assisting physicians with exceptional healthcare delivery but also on promoting compliance with the industry's best practices.

Healthcare Solutions, Inc., headquartered in Glen Cove, New York. Please visit www.hscorp.biz for additional information.

CONTACT:

Jonathan Loutzenhiser
SVP Healthcare Solutions
Email: IR@HScorp.Biz
Email: MR@HScorp.Biz
Phone: +1 (866) 668-2188

SOURCE: Healthcare Solutions Holdings, Inc.

ReleaseID: 571348

WENZHOU, CHINA / ACCESSWIRE / December 26, 2019 / On Christmas day, December 25, 2019, the image of China's bay area appeared again on the screens of Nasdaq and Reuters in New York's Times Square. Different from the past, the protagonist is not the Guangdong-Hong Kong-Macao greater bay area, but Wenzhou.

Wenzhou is one of the most important seaports in China.As early as the Southern Song Dynasty, it was the "first port" of China.After the reform and opening up, Wenzhou once became the "window" of China, one of the cradles of China's private economy, and a famous historical and cultural city with international influence.

Nearly 700,000 Wenzhou people are developing in 131 countries and regions in the world, of which 380,000 are developing in 58 countries and regions along the "One Belt And One Road" line. Some research institutions have pointed out that the total "Wenzhou people economy" reached 1.2 trillion yuan in 2018.

The action plan for the construction of the greater bay area of Zhejiang province was released in 2018. The integrated development of the Yangtze river delta was upgraded to a national strategy in 2019, and Wenzhou was listed as one of the 27 central regional cities. Wenzhou released the "greater bay area construction action plan (2019-2022)" in May 2019. By 2022, the economic aggregate of Wenzhou greater bay area will reach 800 billion yuan, initially forming an international bay area city pattern of integrated development. Wenzhou's "bay area era" begins.

Binjiang CBD, located in the center of Wenzhou metropolitan area, is the central connection point of Wenzhou from "Binjiang Era" to "Binhai Era" and has a very important strategic position.Binjiang CBD is one of the three major financial agglomeration areas in Zhejiang province. It will become the "Lujiazui" of Wenzhou, which integrates headquarters, shopping, finance, star-level hotels, exhibition culture and residence and entertainment.

Every world-class bay area city needs world-class engine and urban complex endorsement.In the New York bay area of the USA, there are Times Square and Rockefeller Center.In the London bay area, there's Canary Wharf.In the Tokyo bay area of Japan, there are the hills of Roppongi.In the Guangdong-Hong Kong-Macao greater bay area of China, there is the Shenzhen bay complex of China Resources.

There is also a world-class bay area complex — China Resources Land era complex in Binjiang CBD center of Wenzhou.The project is located in the north section of the central axis of the Wenzhou metropolitan area, about 10.8 kilometers in the center along the Oujiang river of the Binjiang business district.It is reported that the project will be built into a high-end commercial complex of about 700,000 square meters, covering about 330 meters of skyscraper office buildings, high-end business of Vientiane, luxury hotels, luxury apartments, overlooking the river mansion and other colorful business forms, making Wenzhou shine brightly on the map of the global bay area.

It is reported that the global debut of China Resources Land era complex is its nearly 80,000 square meters overlooking the river mansion. As the latest batch of China Resources Land residential products, Jiu Yue is not only a rare riverside residential in the CBD, but also has its own super IP.Central location,beautiful river scenery and TOP class business present not only the city cover of Wenzhou, but also a new TOP lifestyle.

Jiu Yue of China Resources Land, with a covered area of about 125-180㎡, is in line with the great process.

CONTACT: 

Person: chenjian
Email: chenjian375@crland.com.cn
TEL: + 86 (577) 85508888

Temporary exhibition hall address: Shangri-la Hotel, Sheraton Hotel, Wenzhou, China.

Project address: Binjiang CBD center, Wenzhou, China

SOURCE: crland

ReleaseID: 571266

LOS ANGELES and SAN DIEGO, CA / ACCESSWIRE / December 26, 2019 / IDW Media Holdings, Inc., (OTC PINK:IDWM), an integrated media company, is wrapping up a 2019 loaded with significant accomplishments and is prepared for a transformative 2020.

"IDW made great progress in the past year and will be serving up a feast for readers and viewers in 2020," said IDW's Chairman and CEO, Howard Jonas. "Across the company, we are working with renowned creators to bring compelling characters and their stories to entertain audiences globally."

IDW Entertainment (IDWE) has four series airing in December or scheduled for launch in 2020:

"V Wars," IDWE's vampire thriller, debuted on Netflix on December 5th. The binge-worthy series with a 10-episode first season, stars Ian Somerhalder and was produced by High Park Entertainment in Toronto (CA). The series is based upon Jonathan Maberry's IDW Publishing comic book series. After release, "V Wars" rocketed to the top of Netflix's trending and most popular lists.
"October Faction" premieres on Netflix January 23rd. The much-anticipated show is based on the IDW Publishing comics of Steve Niles and Damien Worm as adapted by showrunner Damian Kindler and is also produced by High Park Entertainment. The series, starring Tamara Taylor and J.C. MacKenzie, chronicles the veteran monster-hunting couple Fred and Deloris Allen and their teenage twins – who move to a small town in upstate New York in a spectacularly unsuccessful attempt to bury their past.
"Locke & Key" premieres on Netflix on February 7th. The show is based on the critically acclaimed hit graphic novels of Joe Hill and Gabe Rodriguez, also published by IDW. After their father is murdered, three Locke family siblings return to their ancestral home, Keyhouse Manor, and to its keys that access other fearsome dimensions.
Season 4 (S4) of "Wynonna Earp" is now in production. Thanks to energetic and tireless lobbying by its enthusiastic fans, the gun-slinging great-great-granddaughter of Wyatt Earp will continue bringing paranormal demons to justice. The show, created by Emily Andras and starring Melanie Scrofano, is based on the IDW comics of Beau Smith. S4 is coming to the small screen through a partnership of IDW with Syfy, Space and Seven24 Films. The initial S4 episode could air on Syfy as early as this summer.

IDW Publishing (IDWP) comics and graphic novels continue to break new ground:

"They Called Us Enemy" (TCUE) has been named the best graphic novel of 2019 by the Publisher's Weekly Critics Poll. In TCUE, actor and activist George Takei chronicles his family's imprisonment in U.S. internment camps during WWII.

TCUE has been lauded as a ‘Best Book of the Year' by:

Amazon
The New York Public Library
The School Library Journal
Publishers Weekly
Kirkus Reviews

In June of 2020, IDWP plans to release TCUE in Spanish. "It's been my life's mission to tell the story of the cruel and unjust incarceration of Japanese Americans during World War II," Mr. Takei said in a recent speech to educators. "I am thrilled to make the story accessible to a community that right now-today-is facing attacks that are all too familiar. This [Spanish language] edition is especially meaningful to me since I was raised in the Spanish-speaking community of East L.A., which welcomed my family after four years of imprisonment."

The Spanish-language edition of TCUE is only the first book in a multi-phase, multi-title program to release fan-favorite graphic novels in Spanish language to the North American readers for the first time in the company's history.

In December, IDWP released its 100th edition of the beloved "Teenage Mutant Ninja Turtles" comic. The Company has been publishing the franchise for eight years, though its roots go back to its founding by Kevin Eastman and Peter Laird in the 1980s. The current series, a collaborative effort led by Eastman and Tom Walz, has seen the teenage reptiles evolve and adapt while continuing to connect with fans around the world.

IDWP released the first edition of "Dying is Easy" in December. "DiE" is a ground-breaking mini-series by New York Times best-selling author Joe Hill (also of "Locke & Key" fame) and co-creator/artist Martin Simmonds. The first edition introduces Syd Homes – a disgraced ex-cop and darkly bitter stand-up comic who quickly finds himself on the wrong side of the law.

IDWP also proudly launched "Wellington," a new comics series of the fictional adventures of an historical figure, Arthur Wellesley, 1st Duke of Wellington and twice British Prime Minister, as he hunts down the demons wreaking havoc in 19th-century England. "Wellington" is a spinoff of "Lore," a hugely successful IDWP series created by Aaron Mahnke. For "Wellington", Mahnke collaborates with sci-fi and fantasy author and comics creator Delilah S. Dawson.

Coming in 2020 from IDWP — a graphic serial adaptation of the best-selling ‘Sleeping Beauties' a terrifying, cautionary novel by Stephen King and his son, Owen King. Novelist Rio Youers and artist Alison Sampson collaborate to produce this spectacular ten-part series.

Also slated for release in 2020: New Yorker Cartoonist Shannon Wheeler's graphic novel adaptation of "The Mueller Report." The book transforms the dry language of the original report into a creative, sometimes comic, and always insightful re-imagining.

"IDW Publishing is well-poised to enter its twenty-first year with its most diverse slate of content ever," said Chris Ryall," IDW Publishing's President & Publisher/Chief Creative Officer. "And beyond developing new editorial directives to better suit the ever-changing needs of the publishing world, we have spent considerable time leading up to 2020 in identifying and cultivating new audiences, additional markets, and interesting new channels of distribution, too. We are very excited about expanding our mission of creating, marketing, and releasing captivating new comics and graphic novels to the world."

All statements above that are not purely about historical facts, including, but not limited to, those in which we use the words "believe," "anticipate," "expect," "plan," "intend," "estimate," "target" and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors. Our filings with the SEC provide detailed information on such statements and risks, and should be consulted along with this release. To the extent permitted under applicable law, we assume no obligation to update any forward-looking statements.

About IDW Media Holdings:

IDW Media Holdings, Inc. (OTCPINK: IDWM) is an integrated media company. IDW's businesses include IDW Publishing – a leading American publisher of comic books and graphic novels, IDW Entertainment – a producer and distributor of franchise content through television and other media, and CTM Media Group – one of North America's largest distributors of information for tourists and travelers.

Investor Contact:

IDW
Ezra Rosensaft, Chief Financial Officer
ezra@idwmh.com

SOURCE: IDW Media Holdings Inc.

ReleaseID: 571347

NEW YORK, NY and TOKYO, JAPAN / ACCESSWIRE / December 26, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN), a New York-based biopharmaceutical company, and Meiji Seika Pharma Co., Ltd, a Tokyo-based wholly owned subsidiary of Meiji Holdings Co., Ltd. (TYO: 2269), today announced that the companies have entered into a strategic collaboration to form a joint venture to exclusively develop and commercialize KD025 in Japan and certain other Asian countries.

Under the terms of the transaction agreements, Kadmon will receive payments which could exceed $29.0 million, resulting from various potential establishment, development, regulatory and commercial milestones. In addition, Kadmon is eligible to receive double-digit percentage royalty payments on sales of KD025 in the territory.

KD025, Kadmon's ROCK2 inhibitor, is being studied in a pivotal clinical trial in the United States for the treatment of chronic graft-versus-host disease (cGVHD). In October 2018, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to KD025 for the treatment of cGVHD after two or more lines of systemic therapy.

The joint venture, Romeck Pharma, LLC, is domiciled in Japan with shared oversight between Kadmon and Meiji.

"The KD025 data generated to date provides a clear rationale for our desire to partner with Kadmon to develop KD025 to potentially treat a range of inflammatory and fibrotic diseases for Japanese and other Asian patients," said Daikichiro Kobayashi, President and Representative Director of Meiji. "Kadmon is an exciting company with whom we share the same ethical and innovative vision to develop and deliver important medicines to critically ill patients, and we are highly motivated to seek fast-track regulatory approval of KD025 in our region."

"We are pleased to partner with Meiji, a globally respected organization who has commercialized pharmaceuticals in Japan and Asia for over 70 years," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "KD025 is a unique drug candidate with potential to treat many inflammatory and fibrotic diseases, and we hope that this joint venture will, together with our recently announced collaboration with BioNova in China, accelerate access to this drug for patients across East and Southeast Asia."

"Meiji is an ideal partner for the Japanese region: their drug development experience and commitment to advancing KD025 expeditiously gives us great confidence in this joint venture to bring KD025 to additional patients in need," added Faical Miyara, Ph.D., Senior Vice President, Business Development of Kadmon.

About Kadmon

Kadmon is a biopharmaceutical company developing innovative products for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases as well as immuno-oncology.

About Meiji

In order to protect and improve people's health and lives, Meiji Seika Pharma strives to respond to diversified medical needs and contributes to the well-being of people worldwide.

Address: Chuo-ku, Tokyo Japan
President and Representative Director: Daikichiro Kobayashi
https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

Forward Looking Statements

This press release contains forward-looking statements. Such statements may be preceded by the words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe, Japan and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel; (xx) our ability to achieve cost savings and other benefits from our efforts to streamline our operations and to not harm our business with such efforts; (xxi) the use of proceeds from our recent public offerings; (xxii) the potential benefits of any of our product candidates being granted orphan drug designation; (xxiii) the future trading price of the shares of our common stock and impact of securities analysts' reports on these prices; (xxiv) the possibility that we will not be able to successfully operate our joint venture with Meiji; and/or (xxv) other risks and uncertainties. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact Information

Ellen Cavaleri, Investor Relations
646.490.2989
ellen.cavaleri@kadmon.com

SOURCE: Kadmon Holdings, Inc.

ReleaseID: 571334